Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients

Elisabetta Schiaroli, Daniela Francisci, Giovanni Brachelente et al.|Journal of Clinical Virology|2023

Cited by 3